The company is best known for its drug, Ingrezza. Ingrezza treats tardive dyskinesia and chorea associated with Huntington's disease. Both are movement disorders. But in the fourth quarter ...

As with other drugs, Ingrezza (valbenazine) can cause side effects, such as drowsiness and parkinsonism. If you are unable to tolerate Ingrezza’s side effects, talk with your doctor or ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

2024 marked a significant milestone for Neurocrine with INGREZZA achieving record sales, showing an impressive increase of approximately $475 million. This robust performance underscores the drug ...

The firm sees potential upside for Neurocrine shares with multiple commercial products, including Ingrezza and Crenessity, and late stage programs in schizophrenia and depression, the analyst ...

The payer coverage changes suggests gradually increasing stringency around Ingrezza utilization, which may help explain Q4 weakness and the company’s disappointing FY25 guidance, the analyst ...